ITG-HM4V8-100μg / 询价
ITG-HM4V8-500μg / 询价
ITG-HM4V8-500μgx2 / 询价
Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein
Recombinant Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus It contains Phe31-Val992(ITGAV) acidic tail & Glu43-Arg684(ITGB8) basic tail [Accession | P06756-1(ITGAV)&P26012-1(ITGB8)].
The protein has a predicted MW of 114 kDa (ITGAV) and 76 kDa (ITGB8). Due to glycosylation, the protein migrates to 90-150 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human ITGAV&ITGB8 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human ITGAV&ITGB8 is greater than 95% as determined by SEC-HPLC.
Immobilized Human ITGAV&ITGB8, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Human Latent TGF beta 1, His Tag with the EC50 of 0.85 μg/ml determined by ELISA.
Integrin αVβ8 is a heterodimeric cell surface receptor involved in various cellular processes, including cell adhesion, migration, and signaling. It is recognized for its unique role in activating TGF-β and has been implicated in immune responses and tissue homeostasis. Due to its distinctive structure and function, integrin αVβ8 is considered atypical among integrin family members.
αVβ8; Integrin alpha V beta 8; TGAV&ITGB8;Integrin alpha V β 8
[1] Song G, Luo BH. Atypical structure and function of integrin αV β8. J Cell Physiol. 2021 Jul;236(7):4874-4887. doi: 10.1002/jcp.30242. [2] Dodagatta-Marri E, Ma HY, Liang B, Li J, Meyer DS, Chen SY, Sun KH, Ren X, Zivak B, Rosenblum MD, Headley MB, Pinzas L, Reed NI, Del Cid JS, Hann BC, Yang S, Giddabasappa A, Noorbehesht K, Yang B, Dal Porto J, Tsukui T, Niessen K, Atakilit A, Akhurst RJ, Sheppard D. Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. Cell Rep. 2021 Jul 6;36(1):109309. doi: 10.1016/j.celrep.2021.109309.
